Bay­er buys li­cense to Cedil­la pre­clin­i­cal can­cer pro­gram; MEI Phar­ma says no to un­so­licit­ed of­fer

Bay­er has ac­quired ex­clu­sive rights to Cedil­la Ther­a­peu­tics’ pre­clin­i­cal can­cer drug can­di­dates for an undis­closed amount.

Bay­er an­nounced Thurs­day morn­ing that it is ac­quir­ing the li­cense for Cedil­la’s pre­clin­i­cal Cy­clin E1/CDK2 com­plex in­hibitors. Cy­clin E1 ac­ti­vates CDK2, and the two dri­ve can­cer pro­gres­sion and are over­ex­pressed in can­cer cells.

Bay­er did not dis­close what in­di­ca­tions it will be pur­su­ing un­der this part­ner­ship. The deal is struc­tured tra­di­tion­al­ly — Bay­er will pay Cedil­la an undis­closed amount up­front, and the lat­ter is al­so el­i­gi­ble for po­ten­tial de­vel­op­ment and com­mer­cial mile­stones and roy­al­ties. — Lei Lei Wu

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER